CJC-1295 Pre-Surgery Hold Window: How Long to Stop Before Your Procedure

Why the Hold Window Differs by CJC-1295 Variant

The single most important variable in planning a surgical hold is which variant of CJC-1295 you are prescribed. The two compounded forms behave like entirely different pharmacological agents once injected.

CJC-1295 without DAC (also called modified GRF 1-29) has a plasma half-life of roughly 30 minutes, with biologically active GH pulses resolving within 3 to 6 hours [1]. CJC-1295 with DAC covalently binds albumin through a reactive maleimide group, extending the terminal half-life to approximately 6 to 8 days [2]. That difference makes a 72-hour hold safe for one formulation and dangerously inadequate for the other.

The DAC Mechanism Explains the 14-Day Rule

Teichman et al. (J Clin Endocrinol Metab, 2006, N=65) showed that a single subcutaneous dose of CJC-1295 with DAC produced sustained GH elevation lasting up to 8 days and IGF-1 elevation persisting for 9 to 14 days post-injection [2]. At the 14-day mark, mean IGF-1 remained approximately 30 to 40% above pre-dose baseline in the highest-dose cohorts.

A 14-day pre-surgical hold allows at least two half-lives of clearance for albumin-bound peptide plus full normalization of the downstream IGF-1 signal, which is the axis most relevant to perioperative metabolic risk [2].

Non-DAC Kinetics Allow a Shorter Window

Modified GRF 1-29 without DAC is enzymatically degraded by dipeptidyl peptidase IV (DPP-IV) within minutes of injection [1]. The pulsatile GH release it triggers mirrors endogenous pulsatility and resolves before the next scheduled dose. A 72-hour hold covers three missed standard injection intervals and is considered sufficient by the HealthRX clinical team for low-to-moderate risk procedures, though your surgeon and anesthesiologist retain final authority.

Physiological Mechanisms That Drive Perioperative Risk

Understanding why GH elevation matters under anesthesia requires knowing what GH does acutely versus chronically. Surgical stress itself triggers a counter-regulatory hormone surge, including cortisol, glucagon, epinephrine, and endogenous GH. Exogenous supraphysiological GH secretion stacks on top of that response.

Insulin Resistance and Glucose Dysregulation

Acute GH excess produces dose-dependent insulin resistance within hours [3]. The FDA-approved GH product somatropin carries a labeling warning specifically about GH-induced impairment of glucose tolerance [4]. Under general anesthesia, glucose monitoring is intermittent. A patient arriving to the OR with elevated IGF-1 from a recent DAC injection may exhibit exaggerated intraoperative hyperglycemia that the anesthesia team is not prepared for.

The Society for Ambulatory Anesthesia recommends a target intraoperative glucose of 140 to 180 mg/dL for non-diabetic patients [5]. Supraphysiological GH activity can push fasting glucose 20 to 40 mg/dL above baseline even in the absence of diagnosed diabetes, as demonstrated in GH replacement trials where glucose AUC increased significantly during the first 4 weeks of therapy [3].

Fluid Retention and Sodium Handling

GH stimulates renal tubular sodium reabsorption via IGF-1-mediated effects on the proximal tubule [6]. Patients using the DAC variant at doses of 1 to 2 mg per week commonly report mild peripheral edema during the first 4 to 6 weeks of therapy. Arriving to surgery in a state of relative sodium and fluid excess complicates intraoperative fluid management and may increase the risk of pulmonary edema in patients with borderline cardiac reserve.

Wound Healing: A Double-Edged Consideration

GH and IGF-1 accelerate cellular proliferation and collagen synthesis [7]. Some surgeons have speculated this could be beneficial perioperatively. The evidence does not support routine continuation for that purpose. Excessive GH signaling during the acute inflammatory phase of wound repair may disrupt the orderly progression from inflammation to proliferation, and the insulin resistance effect on fibroblast glucose uptake outweighs any theoretical anabolic benefit in the first 72 hours post-incision [7].

Anesthesia-Specific Drug Interactions

CJC-1295 itself does not appear in standard drug interaction databases because it is a compounded peptide without an NDA. The interactions are pharmacodynamic, not pharmacokinetic.

Volatile Anesthetics and GH Secretion

Isoflurane, sevoflurane, and desflurane each suppress hypothalamic GHRH release to varying degrees during deep anesthesia [8]. CJC-1295 with DAC bypasses hypothalamic regulation entirely by directly stimulating pituitary GH release via the GHRH receptor. The net effect in a patient who has not held the DAC variant is unpredictable GH output that does not dampen under volatile agents the way endogenous GH does.

Opioids and GH Axis Interactions

Opioids acutely stimulate GH secretion through mu-receptor pathways in the hypothalamus [8]. In a patient with already-elevated GH from CJC-1295, perioperative opioid administration may produce additive GH elevation in the first 6 to 12 hours post-operatively. While no randomized controlled trial has specifically examined this combination, the mechanistic concern is well established in neuroendocrine literature [8].

Corticosteroids as Dexamethasone Anti-Emesis

Dexamethasone 4 to 8 mg is routinely given at induction for post-operative nausea. Glucocorticoids acutely blunt pituitary GH secretion through somatostatin pathway stimulation [9]. In a patient who has properly held CJC-1295, this creates no meaningful interaction. In a patient who has not held the DAC variant, the net GH effect becomes genuinely unpredictable.

Procedure-Stratified Hold Recommendations

Not all procedures carry the same metabolic demand. The HealthRX clinical team applies a tiered approach based on procedure duration, expected fluid shifts, and glucose monitoring intensity.

Minor Procedures Under Local Anesthesia

Examples include mole removal, minor dental work, and joint injections. For non-DAC CJC-1295, a 72-hour hold remains appropriate. For the DAC variant, the HealthRX team recommends a minimum 7-day hold for procedures not requiring general anesthesia, based on the Teichman pharmacokinetic data showing GH normalization around day 7 to 9 in low-to-moderate dose cohorts [2].

Major Elective Surgery Under General or Neuraxial Anesthesia

Examples include abdominal, orthopedic, cardiovascular, and bariatric procedures. The 14-day hold applies universally for the DAC variant. For non-DAC modified GRF, the hold extends to 5 to 7 days before major procedures, accounting for the broader metabolic disruption and longer fasting periods involved [3].

Emergency Surgery

If a patient requires emergency surgery and has received a DAC dose within the past 14 days, the anesthesia team must be informed of the injection date and estimated dose. Continuous glucose monitoring every 60 minutes intraoperatively is appropriate. The surgical and anesthesia teams should anticipate possible insulin resistance and plan insulin infusion protocols accordingly [5].

How to Confirm the Hold Is Complete Before Surgery

Stopping CJC-1295 on the right day is necessary but not sufficient. Two lab values confirm adequate washout before the OR.

IGF-1 Level

IGF-1 reflects integrated GH secretion over 24 to 48 hours and is the most practical surrogate for active GH-axis stimulation. An IGF-1 within the age- and sex-adjusted reference range (typically 100 to 300 ng/mL for adults aged 30 to 60) suggests adequate washout. An IGF-1 more than 1.5 times the upper limit of the reference range in the context of a recent DAC dose is a signal to extend the hold [2].

Fasting Glucose

A fasting glucose <100 mg/dL on the morning of pre-operative labs confirms that GH-driven insulin resistance has resolved to baseline. A glucose between 100 and 125 mg/dL requires communication with the anesthesiologist, even without a diabetes diagnosis [5].

Post-Surgical Restart Timing

The same physiological reasoning that governs the pre-operative hold applies in reverse for restart timing.

Standard Restart Window

The HealthRX clinical team recommends waiting a minimum of 14 days after primary wound closure before restarting non-DAC modified GRF 1-29, and a minimum of 21 to 28 days before restarting the DAC variant. The acute inflammatory phase of healing runs approximately 3 to 5 days, the proliferative phase runs 5 to 21 days, and the remodeling phase begins around day 21 [7]. Resuming a GH secretagogue during the inflammatory phase risks disrupting the sequential cytokine cascade.

Restart Dose

At restart, the HealthRX protocol calls for returning to the lowest previously effective dose rather than the maintenance dose the patient was on before surgery. This is consistent with how compounding pharmacies and prescribing physicians typically approach reinitiation after any metabolic interruption. IGF-1 should be rechecked at 4 weeks post-restart to confirm the axis has responded appropriately.

Situations That Delay Restart Further

Three clinical scenarios push the restart window past 28 days: active wound infection, post-operative steroid use lasting more than 7 days, and new-onset post-operative hyperglycemia with fasting glucose persistently above 126 mg/dL. In each case, the underlying issue must resolve before re-initiating a GH secretagogue [3][4].

What the 2006 Teichman Trial Tells Surgeons

The Teichman et al. Paper remains the primary pharmacokinetic reference for CJC-1295 with DAC because no larger randomized controlled trial has been completed in the 19 years since publication. The trial enrolled 65 healthy adults aged 21 to 61 and assigned them to single or multiple subcutaneous doses of CJC-1295 DAC (30 to 60 mcg/kg) versus placebo [2].

Key findings directly relevant to surgical planning include:

• Mean GH area under the curve was elevated for 6 full days after a single dose
• IGF-1 rose significantly within 24 hours, peaked at day 2 to 3, and remained above baseline through day 14 in the highest-dose groups
• No serious adverse events were reported, but transient injection-site reactions and mild facial flushing occurred in roughly 27% of participants
• Dose-proportional increases in both GH and IGF-1 were observed, meaning higher compounded doses extend the active window further than 14 days [2]

The HealthRX clinical team notes that compounded doses prescribed in practice (often 2 to 5 mg per week for the DAC variant) commonly exceed the trial's 30 to 60 mcg/kg range. At a body weight of 80 kg, 60 mcg/kg equals 4.8 mg. Patients on higher weekly doses should plan for a full 21-day hold rather than 14 days.

The American Association of Clinical Endocrinology (AACE) guidelines on growth hormone therapy state: "IGF-1 should be maintained within age- and sex-specific reference ranges to minimize metabolic side effects" [9]. While AACE guidance targets approved GH products, the underlying principle applies directly to any GH-secretagogue context.

Informing Your Surgical and Anesthesia Teams

CJC-1295 does not appear in standard drug reconciliation databases. Patients who do not proactively disclose use will not be screened for it. This is a documentation gap with real perioperative consequences.

What to Tell Your Surgeon

Disclose the specific variant (DAC vs. Non-DAC), the dose per injection, and the date of the last injection. Give the surgeon a copy of your prescribing physician's contact information. The FDA's Office of Pharmaceutical Quality has published guidance on compounded preparations noting that 503A compounded drugs require prescriber oversight and should be documented in the medical record [10].

What to Tell Your Anesthesiologist

Tell your anesthesiologist the last injection date, the dose, and that the drug is a pulsatile GH secretagogue with a prolonged half-life in the DAC form. Request that intraoperative glucose be checked every 60 minutes if the hold window was less than 14 days for the DAC variant. The anesthesiologist should also know that standard volatile agents will not suppress this drug's GH stimulation the way they suppress endogenous GHRH-driven GH release [8].

Compounding Pharmacy Considerations

CJC-1295 is not FDA-approved. It is dispensed only through 503A compounding pharmacies under an individual patient prescription. Vial labeling varies by pharmacy, and the distinction between DAC and non-DAC is not always clear on the label itself.

If a patient is uncertain which formulation they have, the safest clinical default is to treat it as the DAC variant and apply the 14-day hold. Confirming the formulation with the dispensing pharmacy before any elective procedure is the correct step and requires only a phone call [10].

The FDA has noted that compounded GH secretagogues fall outside the scope of FDA-approved biologics and that prescribers bear responsibility for informed-consent documentation [10]. Prescribers at HealthRX document formulation details, dose, and injection schedule in the patient chart specifically to support scenarios like pre-operative reconciliation.

Summary Table: Hold Windows by Variant and Procedure Type

| Formulation | Minor Procedure (Local) | Major Surgery (General Anesthesia) | Emergency Surgery | |---|---|---|---| | CJC-1295 without DAC (modified GRF 1-29) | 72 hours | 5 to 7 days | Disclose to team; glucose monitoring q60 min | | CJC-1295 with DAC | 7 days | 14 days (21 days if dose >3 mg/week) | Disclose to team; glucose monitoring q60 min; consider insulin infusion protocol |